1887
  1. Home
  2. Eurosurveillance
  3. Volume 27, Issue 1, 06/Jan/2022
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

Serum samples were collected pre- and post-booster vaccination with Comirnaty in 626 participants (aged ≥ 50 years) who had received two Comirnaty doses < 30 days apart, two Comirnaty doses ≥ 30 days apart or two Vaxzevria doses ≥ 30 days apart. Irrespective of primary vaccine type or schedule, spike antibody GMTs peaked 2–4 weeks after second dose, fell significantly ≤ 38 weeks later and rose above primary immunisation GMTs 2–4 weeks post-booster. Higher post-booster responses were observed with a longer interval between primary immunisation and boosting.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2022.27.1.2101114
2022-01-06
2024-12-27
/content/10.2807/1560-7917.ES.2022.27.1.2101114
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/27/1/eurosurv-27-1-2.html?itemId=/content/10.2807/1560-7917.ES.2022.27.1.2101114&mimeType=html&fmt=ahah

References

  1. Andrews N, Stowe J, Kirsebom F, Gower C, Ramsay ME, Lopez Bernal J. Effectiveness of BNT162b2 (Comirnaty, Pfizer-BioNTech) COVID-19 booster vaccine against covid-19 related symptoms in England: test negative case-control study. medrxiv. 2021:2021.11.15.21266341. Preprint.
  2. Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis. 2022;22(1):35-42.  https://doi.org/10.1016/S1473-3099(21)00475-8  PMID: 34461056 
  3. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385(7):585-94.  https://doi.org/10.1056/NEJMoa2108891  PMID: 34289274 
  4. United Kingdom Health Security Agency (UKHSA). JCVI statement regarding a COVID-19 booster vaccine programmed for winter 2021 to 2022. London: UKHSA; 15 Nov 2021. Available from: https://www.gov.uk/government/news/jcvi-issues-advice-on-covid-19-booster-vaccines-for-those-aged-40-to-49-and-second-doses-for-16-to-17-year-olds
  5. United Kingdom Health Security Agency (UKHSA). The Joint Committee on Vaccination and Immunisation (JCVI). JCVI issues advice on COVID-19 booster vaccines for those aged 40 to 49 and second doses for 16 to 17 year olds. London: UKHSA; 15 Nov 2021. Available from: https://www.gov.uk/government/news/jcvi-issues-advice-on-covid-19-booster-vaccines-for-those-aged-40-to-49-and-second-doses-for-16-to-17-year-olds
  6. United Kingdom Health Security Agency (UKHSA). Weekly national Influenza and COVID-19 surveillance report: week 27 report (up to week 26 data). London: UKHSA; 2021. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1000373/Weekly_Flu_and_COVID-19_report_w27.pdf
  7. Subbarao S, Warrener LA, Hoschler K, Perry KR, Shute J, Whitaker H, et al. Robust antibody responses in 70-80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021. Euro Surveill. 2021;26(12).  https://doi.org/10.2807/1560-7917.ES.2021.26.12.2100329  PMID: 33769252 
  8. Amirthalingam G, Lopez Bernal J, Andrews N, Whitaker H, Gower C, Stowe J, et al. Higher serological responses and increased vaccine effectiveness demonstrate the value of extended vaccine schedules in combatting COVID-19 in England. medrxiv. 2021:2021.07.26.21261140. Preprint.
  9. Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021;39(32):4423-8.  https://doi.org/10.1016/j.vaccine.2021.05.063  PMID: 34210573 
  10. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205-11.  https://doi.org/10.1038/s41591-021-01377-8  PMID: 34002089 
  11. Perkmann T, Koller T, Perkmann-Nagele N, Klausberger M, Duerkop M, Holzer B, et al. Spike protein antibodies mediate the apparent correlation between SARS-CoV-2 nucleocapsid antibodies and neutralization test results. Microbiol Spectr. 2021;9(1):e0021821.  https://doi.org/10.1128/Spectrum.00218-21  PMID: 34132615 
  12. Jung K, Shin S, Nam M, Hong YJ, Roh EY, Park KU, et al. Performance evaluation of three automated quantitative immunoassays and their correlation with a surrogate virus neutralization test in coronavirus disease 19 patients and pre-pandemic controls. J Clin Lab Anal. 2021;35(9):e23921.  https://doi.org/10.1002/jcla.23921  PMID: 34369009 
  13. Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398(10316):2093-100.  https://doi.org/10.1016/S0140-6736(21)02249-2  PMID: 34756184 
  14. Gardener BJ, Kilpatrick AM. Third doses of COVID-19 vaccines reduce infection and transmission of SARS-CoV-2 and could prevent future surges in some populations. medrxiv. 2021: 2021.10.25.21265500. Preprint.
Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Georgina+Ireland&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ireland Georgina</a>, <a href="/search?value1=Heather+Whitaker&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Whitaker Heather</a>, <a href="/search?value1=Shamez+N+Ladhani&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ladhani Shamez N</a>, <a href="/search?value1=Frances+Baawuah&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Baawuah Frances</a>, <a href="/search?value1=Sathyvani+Subbarao&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Subbarao Sathyvani</a>, <a href="/search?value1=Ezra+Linley&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Linley Ezra</a>, <a href="/search?value1=Lenesha+Warrener&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Warrener Lenesha</a>, <a href="/search?value1=Michelle+O%E2%80%99Brien&option1=author&noRedirect=true" class="nonDisambigAuthorLink">O’Brien Michelle</a>, <a href="/search?value1=Corinne+Whillock&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Whillock Corinne</a>, <a href="/search?value1=Oliver+Martin&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Martin Oliver</a>, <a href="/search?value1=Paul+Moss&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Moss Paul</a>, <a href="/search?value1=Mary+E+Ramsay&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ramsay Mary E</a>, <a href="/search?value1=Gayatri+Amirthalingam&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Amirthalingam Gayatri</a>, <a href="/search?value1=Kevin+E+Brown&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Brown Kevin E</a></span>. Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021. <a href="/content/ecdc">Euro Surveill.</a> 2022;27(1):pii=2101114. <a href="https://doi.org/10.2807/1560-7917.ES.2022.27.1.2101114" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2022.27.1.2101114</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 06 Dec 2021;&nbsp;&nbsp; <span class="generated">Accepted</span>: 21 Dec 2021 </span> </p>
/content/10.2807/1560-7917.ES.2022.27.1.2101114
/content/10.2807/1560-7917.ES.2022.27.1.2101114
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error